VesiCulture / AJ Vaccines - LARVOL DELTA

SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (clinicaltrials.gov) - P3 | N=1135 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (clinicaltrials.gov) - P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Sep 2030 ➔ Sep 2029

Combination therapy • Trial completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (clinicaltrials.gov) - P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: May 2030 ➔ Sep 2030

Combination therapy • Trial completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (clinicaltrials.gov) - P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial primary completion date: May 2030 ➔ Sep 2029

Combination therapy • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - P3 | N=1050 | Recruiting | Sponsor: Janssen Research & Development, LLC | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - P3 | N=1050 | Not yet recruiting | Sponsor: Janssen Research & Development, LLC

Combination therapy • New P3 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) (clinicaltrialsregister.eu) - P3 | N=700 | Ongoing | Sponsor: Janssen-Cilag International NV

New P3 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer